-transparent.png){kind=logo}
The relationship between the pharmacodynamics and pharmacokinetics of isosorbide dinitrate (ISDN) following oral administration of 40 mg of two different models. A model assuming an additive contribution of all active drug-related substances in plasma to pharmacological effect, i.e., finger pulse plethysmograph, resulted in estimates of relative potencies of ISDN:2-MN:5-MN (2-MN:2-isosorbide mononitrate; 5-MN:5-isosorbide mononitrate) as being 1:0.1:0.025. The data analysis using a receptor model (plasma concentration-effect curves) yielded sigmoid curves yielded sigmoid curves for 2-MN and 5-MN with similar relative potencies in the range of 20-80% of maximum response providing an upper limit for the pharmacodynamic effect due to ISDN, 2-MN or 5-MN in healthy volunteers.
K I Johnson, and
V Gladigau, and
K Schnelle
January 1983,
Arzneimittel-Forschung,
K I Johnson, and
V Gladigau, and
K Schnelle
July 1985,
American heart journal,
K I Johnson, and
V Gladigau, and
K Schnelle
October 1983,
International journal of clinical pharmacology, therapy, and toxicology,
K I Johnson, and
V Gladigau, and
K Schnelle
October 1980,
European journal of clinical pharmacology,
K I Johnson, and
V Gladigau, and
K Schnelle
September 1988,
Arzneimittel-Forschung,
K I Johnson, and
V Gladigau, and
K Schnelle
October 1997,
Biological & pharmaceutical bulletin,
K I Johnson, and
V Gladigau, and
K Schnelle
January 1973,
Clinical pharmacology and therapeutics,
K I Johnson, and
V Gladigau, and
K Schnelle
August 1983,
International journal of clinical pharmacology, therapy, and toxicology,
K I Johnson, and
V Gladigau, and
K Schnelle
June 1977,
Journal of pharmaceutical sciences,
K I Johnson, and
V Gladigau, and
K Schnelle
April 1992,
Archives des maladies du coeur et des vaisseaux,
